EUTECNIQ Sciences

See every page on one mapArrow keys move through results · Enter opens · Esc closes

Company In formation

EUTECNIQ Sciences is being built to turn natural-product chemistry into documented ingredients, technologies and evidence

A proposed platform connecting natural-product discovery, ingredient engineering, delivery, safety and regulatory science, and commercialization.

3company pages
24figures and diagrams
71evidence labels
70registered claims
0staff besides the founder
0patents owned by EUTECNIQ

Status. Being organized as a Delaware corporation, founder-led. No facility, staff besides the founder, customers or patents of its own.

Company pages

Who is building EUTECNIQ, what is planned, and how to get in touch

The company section: two groups inside, pages outside; select a page to open itSite structure
Built from the site navigation; tooltips give each page's figure and tool counts.
Bar on each card: evidence labels on that pageVerified dataPeer-reviewedRegulation or guidanceThird-party estimateProposal, partner or riskSimulation or schematic
Who is building it

Founder

Publications, patents and founder-reported experience, each labeled.

8 figures1 interactive
Plans and contact

Facilities & roadmap

A proposed three-phase facility, released by gates.

8 figures2 interactive
Plans and contact

Contact

Development, suppliers, collaboration or investment.

0 figures
What each company page rests on: share of its evidence labels by kind; select a column to sortCounted at build time
Every evidence label printed on each page, counted when the site is built. Founder-reported experience is grouped with proposals, partner work and risks.
Data table
Evidence labels on each company page, by family, counted at build time
PageLabelsVerified dataPeer-reviewedRegulation or guidanceThird-party estimateProposal, partner or riskSimulation or schematic
Founder4611 (24%)4 (9%)0 (0%)0 (0%)31 (67%)0 (0%)
Heritage: Persian medicine151 (7%)5 (33%)1 (7%)0 (0%)7 (47%)1 (7%)
Facilities & roadmap100 (0%)0 (0%)2 (20%)0 (0%)6 (60%)2 (20%)
Mission and scientific philosophy

The mission is to make natural-product ingredients measurable, documented and dependable

Six principles, each drawn as the decision it governsProposal
Six proposed working principles, each drawn as the decision it governs: identity before activity, measure then claim, decide early and write it down, mechanism before format, models screen and measurements decide, label what is known01Identity before activityMaterialas receivedIdentityconfirmedbyindependentmethodsQuestionsbiological orcommercialNo question is asked of a material whose identity isunconfirmed02Measure, then claimStability resultStability statementBioavailabilityclaimsupportsdoes not supportA claim needs evidence of the matching kind03Decide early and write it downStageGateProceedLoop backStopWritten decision against criteria fixed in advance04Mechanism before formatLimitsuch assolubility ordissolutionDeliverysystemchosen forthat limitTestagainst thatlimitA delivery system is chosen for the limit itaddresses and tested against it05Models screen; measurements decideoptionsoptionsoptionsoptionsoptionsoptionsoptionsoptionsoptionsModel rankslabeled as amodel resultfewer experimentsfewer experimentsMeasurementdecidesSimulations rank options and save experiments;they do not replace measurement06Label what is knownVerified factPublished evidenceRegulatory requirementFounder-reported experienceProposalSimulationStatements on this site carry these evidence labelsSix proposed working principles, each drawn as the decision it governs01Identity before activityMaterialas receivedIdentityconfirmed byindependentmethodsQuestionsbiological orcommercialNo question is asked of a material whose identity isunconfirmed02Measure, then claimStability resultStability statementBioavailabilityclaimsupportsdoes not supportA claim needs evidence of the matching kind03Decide early and write it downStageGateProceedLoop backStopWritten decision against criteria fixed in advance04Mechanism before formatLimitsuch assolubility ordissolutionDeliverysystemchosen for thatlimitTestagainst thatlimitA delivery system is chosen for the limit it addresses andtested against it05Models screen; measurements decideoptionsoptionsoptionsoptionsoptionsoptionsoptionsoptionsoptionsModel rankslabeled as amodel resultfewer experimentsfewer experimentsMeasurementdecidesSimulations rank options and save experiments; they do notreplace measurement06Label what is knownVerified factPublished evidenceRegulatory requirementFounder-reported experienceProposalSimulationStatements on this site carry these evidence labels
Proposed working principles of EUTECNIQ Sciences. Schematic; no EUTECNIQ work has been performed.
Text version of the six principles
01

Identity before activity

No biological or commercial question is asked of a material whose identity has not been confirmed by independent methods.

02

Measure, then claim

A claim needs evidence of the matching kind. A stability result supports a stability statement, not a bioavailability claim.

03

Decide early and write it down

Each development stage ends in a written proceed, loop-back or stop decision against criteria fixed in advance.

04

Mechanism before format

A delivery system is chosen for the limit it addresses, such as solubility or dissolution, and is tested against that limit.

05

Models screen; measurements decide

Simulations and machine-learning models rank options and save experiments. They do not replace measurement, and their outputs are labeled as model results.

06

Label what is known

Statements on this site carry evidence labels: verified fact, published evidence, regulatory requirement, founder-reported experience, proposal or simulation.

Explanation, details and sources

Proposed mission: help bring natural-product ingredients and technologies to market with their identity, composition, safety and performance measured and written down, so that customers, partners and regulators can rely on them.

These principles are a proposal for how the company would work. How they would apply stage by stage is on the platform page.

Where things stand

Today the company is its founder and a plan; everything else is proposed

Two items exist today; seven are proposals with a next stepCompany status Plan
Where EUTECNIQ stands on October 2026: an entity in formation and its founder exist; the facility, laboratory, customers, intellectual property, accreditations, partnerships and first-party data do not. Each has a proposed next step.ItemTodayProposed next stepLegal entityLegal entity: existsBeing organized (Delaware)Formation, then a board with independent directorsPeoplePeople: existsThe founder onlyRoles recruited by phase as gates are metFacilityFacility: does not exist yetNone; no site selectedA phased facility released by gatesLaboratoryLaboratory: does not exist yetNone operatingPhase I laboratory core, then pilot and commercialCustomers and revenueCustomers and revenue: does not exist yetNoneServices first, then ingredients and licensingIntellectual propertyIntellectual property: does not exist yetNone ownedIP terms agreed before project work startsAccreditationsAccreditations: does not exist yetNoneMilestones on the quality-system pagePartnershipsPartnerships: does not exist yetNone signedQualified partners for specialist workFirst-party dataFirst-party data: does not exist yetNone; no experiment runStructured records from the first measurement
Status as stated by the company, October 2026. The right-hand column is a plan, not a commitment; full wording in the table below.
Show the table (9 rows)
ItemTodayPlan Proposal
Legal entityBeing organized as a Delaware corporation (in formation).Completion of formation, then a board that includes independent directors.
PeopleThe founder, Dr. Amir H. Mehrkesh, is the only person working on the company.Roles recruited by phase as gates are met (below).
FacilityNone. No site is selected, and no lease or purchase exists.A phased facility in Southern California, released by gates. See the facilities roadmap.
Laboratory capabilitiesNone operating.A Phase I laboratory core, then pilot and commercial phases.
Customers, contracts and revenueNone.Services first, then ingredients, manufacturing and licensing.
Intellectual propertyNone owned. The founder's patents are assigned to Yazaki Corporation.IP from project data, under ownership terms agreed before work starts.
Accreditations, registrations and certificationsNone.Planned milestones are listed on the quality system page.
PartnershipsNone signed.Qualified partners for specialist work (below).
First-party dataNone. No EUTECNIQ experiment has been run.Structured records from the first Phase I measurement.
Scientific leadership and future team

The founder leads today; every other role is planned and would be filled only when its phase is released

No one has been hired and no advisor has been appointed. The roles are listed without names, because none is filled.

Planned roles by phase, released only by the gates, with independent quality oversightProposal
The founder today, then planned roles in three phases released by Gate 1 and Gate 2, with a planned board, an independent head of quality reporting to the board, and a planned scientific advisory boardBoard · plannedFounder and independent directorsAn independent head of quality would report to the board, sothat release decisions cannot be overruled by commercialpressureTodayFounderDr. Amir H. Mehrkesh,the only person workingon the companyPhase I · proposed 2027Laboratory coreHead of quality (independent)Director of analytical sciencesComputational and data-scienceleadFinance leadCommercial leadGate 1Phase II · after Gate 1Pilot processVP of R&D or chief scientific officerHead of manufacturingRegulatory lead with CMCexperienceGate 2Phase III · after Gate 2Commercial operationsVP of operationsClinical partnerships leadStaffing would followdemonstrated demand, not thecalendarmemberreports to the boardScientific advisory board · planned, no one appointedPharmacognosy and botanicalauthenticationToxicology, including liver safetyClinical pharmacology and naturalproduct–drug interactionsFDA regulation of supplements andbotanical drugsThe founder today, the planned governance and the planned roles in three phases released by gatesTodayFounder: Dr. Amir H. MehrkeshGovernance · plannedBoard: founder and independent directorsIndependent head of quality, reporting to the boardPhase I · proposed 2027 · Laboratory coreHead of quality (independent)Director of analytical sciencesComputational and data-science leadFinance leadCommercial leadGate 1 releases the next phasePhase II · after Gate 1 · Pilot processVP of R&D or chief scientific officerHead of manufacturingRegulatory lead with CMC experienceGate 2 releases the next phasePhase III · after Gate 2 · Commercial operationsVP of operationsClinical partnerships leadScientific advisory board · plannedPharmacognosy and botanical authenticationToxicology, including liver safetyClinical pharmacology and natural product–druginteractionsFDA regulation of supplements and botanical drugs
Planned organization of EUTECNIQ Sciences. No one has been hired and no advisor has been appointed; dashed boxes are unfilled roles.
Text version: leadership, governance and planned roles
Leadership today

Founder

Dr. Amir H. Mehrkesh. His publications, patents (assigned to a former employer) and founder-reported industrial experience are on the founder page. Prior-employer results are that employer's, not EUTECNIQ's.

Governance · planned

Board and independent quality head

A board of the founder and independent directors. An independent head of quality would report to the board, so that release decisions cannot be overruled by commercial pressure in a company that both makes and tests products.

Phase I · proposed 2027

Laboratory core

  • Head of quality (independent)
  • Director of analytical sciences
  • Computational and data-science lead
  • Finance lead
  • Commercial lead
Phase II · after Gate 1

Pilot process

  • Vice president of R&D or chief scientific officer
  • Head of manufacturing
  • Regulatory lead with chemistry, manufacturing and controls (CMC) experience
Phase III · after Gate 2

Commercial operations

  • Vice president of operations
  • Clinical partnerships lead
Advisory · planned

Scientific advisory board

  • Pharmacognosy and botanical authentication
  • Toxicology, including liver safety
  • Clinical pharmacology and natural product–drug interactions
  • FDA regulation of supplements and botanical drugs

Phases and gates are defined on the facilities roadmap. Staffing would follow demonstrated demand, not the calendar.

Responsible sourcing

Sourcing commitments would be written into supplier qualification, not left to a policy statement

Proposed commitments. EUTECNIQ has no supplier relationships yet; each commitment would become a supplier-qualification criterion and an audit check.

Where each sourcing commitment would apply, from source region to the laboratory lot recordProposal
Proposed sourcing commitments placed where they apply, from source region and collection to supplier, receipt and the laboratory lot record, with traceability spanning the whole chain; each commitment becomes a supplier-qualification criterion and an audit checkSource regionWild or cultivated plantpopulationsCollection orcultivationHarvest recordsSupplierQualified and auditedReceipt atEUTECNIQLot receivedLaboratory recordLot ID used in testingSustainable wild collectionNo wild-collected materialwithout a documentedsustainability basis;cultivated sources preferredwhere wild populations are atriskContamination risk atsourcePesticide, heavy-metal andmicrobial risks assessed byregion and cropGood agricultural andcollection practicesSuppliers assessed againstthe WHO GACP guidelines formedicinal plants (2003)Legal acquisitionCITES permits for listedspecies; Nagoya Protocolaccess and benefit-sharingterms where the sourcecountry requires themLabor and commercialtermsSupplier code of conduct onlabor conditions and faircommercial terms, checkedin auditsTraceability to origin: species, plant part, region and harvest or cultivation records for every lot, linked to the laboratory lot IDEach commitment would become a supplier-qualification criterion and an audit check. No supplier relationship exists yet.Proposed sourcing commitments placed where they apply along the chain from source region to laboratory recordSource regionWild or cultivated plant populationsSustainable wild collectionNo wild-collected material without a documentedsustainability basis; cultivated sources preferredwhere wild populations are at riskContamination risk at sourcePesticide, heavy-metal and microbial risks assessedby region and cropCollection or cultivationHarvest recordsGood agricultural and collection practicesSuppliers assessed against the WHO GACPguidelines for medicinal plants (2003)SupplierQualified and auditedLegal acquisitionCITES permits for listed species; Nagoya Protocolaccess and benefit-sharing terms where the sourcecountry requires themLabor and commercial termsSupplier code of conduct on labor conditions and faircommercial terms, checked in auditsReceipt at EUTECNIQLot receivedLaboratory recordLot ID used in testingTraceability to originSpecies, plant part, region and harvest or cultivation recordsfor every lot, linked to the laboratory lot IDEach commitment would become a supplier-qualificationcriterion and an audit check
Proposed commitments. References: CITES Secretariat; Convention on Biological Diversity, Nagoya Protocol; WHO GACP guidelines for medicinal plants (2003). Full citations below.
Text version of the six sourcing commitments

Legal acquisition

Valid CITES permits for species listed under the Convention on International Trade in Endangered Species, and access and benefit-sharing terms where the source country requires them under the Nagoya Protocol.

Traceability to origin

Species, plant part, region and harvest or cultivation records for every lot, linked to the lot ID used in the laboratory.

Good agricultural and collection practices

Suppliers assessed against the WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants (2003).

Sustainable wild collection

No wild-collected material without a documented sustainability basis; cultivated sources preferred where wild populations are at risk.

Labor and commercial terms

A supplier code of conduct on labor conditions and fair commercial terms, checked during audits.

Contamination risk at source

Pesticide, heavy-metal and microbial risks assessed by region and crop as part of supplier qualification.

References: CITES Secretariat, "What is CITES?" cites.org; Convention on Biological Diversity, Nagoya Protocol on Access and Benefit-sharing, cbd.int/abs; World Health Organization, WHO guidelines on good agricultural and collection practices (GACP) for medicinal plants, 2003, who.int.

Partnerships

Specialist work would go to qualified partners under written terms; none is signed

The platform is designed to combine an in-house laboratory core with outside organizations that hold capabilities EUTECNIQ would not build. No partnership, contract or letter of intent exists.

Six partner types around one laboratory core, with four terms on every linkProposal
The in-house laboratory core linked to six types of qualified external partner, none signed, with the four terms every partnership would need on each linkQualified external partners · none signedEUTECNIQ laboratory core · proposedTerms on every link1Quality or service agreement fixing scopeand responsibilities2Partner's accreditation scope or studystatus checked against the specific work3Data ownership, confidentiality andpublication rights agreed before workstarts4Chain of custody for every sample; resultsreturned to one lot recordAccredited testing laboratoriesTests outside the planned in-house scopeContract research organizationsToxicology (GLP where appropriate) andhuman studiesBioanalytical laboratoriesPharmacokinetic measurementsContract manufacturersCommercial scale until a manufacturingphase is justifiedUniversities and research institutesMethod development and publicationInternational ingredient suppliersThrough the proposed global ingredientsfunctionArrows: samples out under chain of custody, results back to one lot recordThe in-house laboratory core, the four terms every partnership would need, and six partner types, none signedEUTECNIQ laboratory core · proposedTerms on every link1Quality or service agreement fixing scope andresponsibilities2Partner's accreditation scope or study statuschecked against the specific work3Data ownership, confidentiality and publicationrights agreed before work starts4Chain of custody for every sample; results returnedto one lot recordAccredited testing laboratoriesTests outside the planned in-house scopeContract research organizationsToxicology (GLP where appropriate) and human studiesBioanalytical laboratoriesPharmacokinetic measurementsContract manufacturersCommercial scale until a manufacturing phase isjustifiedUniversities and research institutesMethod development and publicationInternational ingredient suppliersThrough the proposed global ingredients function
Proposed partnership model. No partnership, contract or letter of intent exists; dashed boxes are partner types, not named organizations.
Text version: partner types and required terms

Who EUTECNIQ would work with

  • Accredited testing laboratories, for tests outside the planned in-house scope.
  • Contract research organizations, for toxicology (GLP where appropriate) and human studies.
  • Bioanalytical laboratories, for pharmacokinetic measurements.
  • Contract manufacturers, for commercial scale until a manufacturing phase is justified.
  • Universities and research institutes, for method development and publication.
  • International ingredient suppliers, through the proposed global ingredients function.

Terms every partnership would need

  • A quality or service agreement that fixes scope and responsibilities.
  • A check that the partner's accreditation scope or study status covers the specific work.
  • Data ownership, confidentiality and publication rights agreed before work starts.
  • Chain of custody for every sample, with results returned to one lot record.
Proposal
News and research updates

Dated developments that shape the platform's priorities

Eleven dated external developments since 2014; eight fall in 2025 and 2026Guidance Verified
Eleven dated external developments from 2014 to October 2026 on a broken time axis, marked by evidence type: FDA and ICH guidance, a proposed rule, verified events and government data, estimates and peer-reviewed papersFDA or ICH guidanceProposed ruleVerified event or government dataEstimate or secondary reportPeer-reviewed2014201620182020202220242025AprJul2026AprJul20272014 and 2019INFOGEST standardizesstatic in vitro digestion2014 and 2019: INFOGEST standardizes static in vitro digestion2014 and 2019: INFOGEST standardizes static in vitro digestionMay 21, 2024ICH M12 on druginteraction studiesreaches Step 4May 21, 2024: ICH M12 on drug interaction studies reaches Step 4Feb 2021Bayesian optimizationbenchmarked againstchemistsFeb 2021: Bayesian optimization benchmarked against chemists2025U.S. herbal supplementsales estimated at$13.231 billion for 20242025: U.S. herbal supplement sales estimated at $13.231 billion for 2024Nov 28, 2025USPTO revisesinventorship guidancefor AI-assistedinventionsNov 28, 2025: USPTO revises inventorship guidance for AI-assisted inventionsAug 11, 2026FDA proposesmandatory GRASnotification; commentsdue Dec 9, 2026(shaded)Aug 11, 2026: FDA proposes mandatory GRAS notification; comments due Dec 9, 2026 (shaded)Sep 25, 2026Joint FDA–EMAworkshop on botanicaldrug developmentSep 25, 2026: Joint FDA–EMA workshop on botanical drug developmentSep 29, 2025FDA letters on NMN andthe drug-exclusionsequenceSep 29, 2025: FDA letters on NMN and the drug-exclusion sequenceMay 2026NCHS reportssupplement use amongU.S. adultsMay 2026: NCHS reports supplement use among U.S. adultsSep 4, 2026FDA requestsinformation on botanicaldrug developmentSep 4, 2026: FDA requests information on botanical drug developmentOct 19–20, 2026FDA finalizes guidanceon NDI identity andsafety informationOct 19–20, 2026: FDA finalizes guidance on NDI identity and safety informationEleven dated external developments, newest first, marked by evidence typeFDA or ICH guidanceProposed ruleVerified event or government dataEstimate or secondary reportPeer-reviewedOct 19–20, 2026: FDA finalizes guidance on NDI identity and safety informationOct 19–20, 2026FDA finalizes guidance on NDI identity andsafety informationSep 25, 2026: Joint FDA–EMA workshop on botanical drug developmentSep 25, 2026Joint FDA–EMA workshop on botanical drugdevelopmentSep 4, 2026: FDA requests information on botanical drug developmentSep 4, 2026FDA requests information on botanical drugdevelopmentAug 11, 2026: FDA proposes mandatory GRAS notificationAug 11, 2026FDA proposes mandatory GRAS notificationMay 2026: NCHS reports supplement use among U.S. adultsMay 2026NCHS reports supplement use among U.S. adults2025Nov 28, 2025: USPTO revises inventorship guidance for AI-assisted inventionsNov 28, 2025USPTO revises inventorship guidance forAI-assisted inventionsSep 29, 2025: FDA letters on NMN and the drug-exclusion sequenceSep 29, 2025FDA letters on NMN and the drug-exclusionsequence2025: U.S. herbal supplement sales estimated at $13.231 billion for 20242025U.S. herbal supplement sales estimated at$13.231 billion for 20242024May 21, 2024: ICH M12 on drug interaction studies reaches Step 4May 21, 2024ICH M12 on drug interaction studies reachesStep 42021Feb 2021: Bayesian optimization benchmarked against chemistsFeb 2021Bayesian optimization benchmarked againstchemists20192014 and 2019: INFOGEST standardizes static in vitro digestion2014 and 2019INFOGEST standardizes static in vitro digestion
Wide layout: the axis is broken at 2025, and 2025–2026 is drawn at a larger scale; shading marks the year the 2025 estimate covers and the open comment period on the proposed GRAS rule. Sources below.
FDA Federal Register documents that mention dietary supplements, 1994–2026, by typeFederal Register data
FDA documents in the Federal Register containing the phrase dietary supplement, 1994 to 2026: 502 in all (110 rules, 86 proposed rules, 306 notices); the busiest years were 1999 and 2016. 2026 is partial.0102030documents per year1994, rules: 41994, proposed rules: 119941995, rules: 21995, proposed rules: 71995, notices: 11996, rules: 71996, proposed rules: 41996, notices: 21997, rules: 81997, proposed rules: 71997, notices: 11998, rules: 61998, proposed rules: 21998, notices: 719981999, rules: 31999, proposed rules: 91999, notices: 182000, rules: 52000, proposed rules: 32000, notices: 92001, rules: 12001, notices: 102002, rules: 12002, notices: 1020022003, rules: 52003, proposed rules: 92003, notices: 122004, rules: 42004, proposed rules: 32004, notices: 82005, rules: 42005, proposed rules: 22005, notices: 82006, rules: 42006, proposed rules: 22006, notices: 820062007, rules: 42007, proposed rules: 42007, notices: 82008, rules: 42008, proposed rules: 12008, notices: 202009, rules: 12009, notices: 192010, rules: 32010, proposed rules: 22010, notices: 920102011, proposed rules: 12011, notices: 142012, rules: 22012, notices: 102013, rules: 22013, proposed rules: 72013, notices: 92014, rules: 52014, proposed rules: 62014, notices: 820142015, rules: 62015, proposed rules: 22015, notices: 152016, rules: 122016, proposed rules: 22016, notices: 152017, rules: 12017, proposed rules: 22017, notices: 82018, rules: 32018, proposed rules: 12018, notices: 1420182019, rules: 22019, proposed rules: 22019, notices: 112020, proposed rules: 22020, notices: 72021, rules: 22021, notices: 62022, rules: 32022, proposed rules: 22022, notices: 1420222023, rules: 32023, proposed rules: 12023, notices: 72024, rules: 12024, proposed rules: 12024, notices: 62025, rules: 12025, notices: 72026, rules: 12026, proposed rules: 12026, notices: 52026*RuleProposed ruleNotice* 2026 to date
Source: Federal Register API, full-text search for "dietary supplement", agency Food and Drug Administration, yearly counts by document type, retrieved October 24, 2026. A document that mentions the phrase is not necessarily about supplements.
Data table
FDA Federal Register documents containing "dietary supplement", by year and type (retrieved 2026-10-24)
YearRulesProposed rulesNoticesTotal
19944105
199527110
199674213
199787116
199862715
1999391830
200053917
2001101011
2002101011
2003591226
200443815
200542814
200642814
200744816
2008412025
2009101920
201032914
2011011415
2012201012
201327918
201456819
2015621523
20161221529
201712811
2018311418
2019221115
20200279
20212068
2022321419
202331711
20241168
20251078
20261157
Text version of the dated developments, newest first
  1. Oct 19–20, 2026

    FDA finalizes guidance on NDI identity and safety information

    It finalizes three sections of the 2016 revised draft: identity, history of use or other evidence of safety, and the summary of the basis for the safety conclusion. Docket FDA-2025-D-6501; 91 FR 66336. FDA guidance

  2. Sep 25, 2026

    Joint FDA–EMA workshop on botanical drug development

    Regulatory perspectives on herbal medicinal and botanical drug product development, held at EMA in Amsterdam and online. Verified

  3. Sep 4, 2026

    FDA requests information on botanical drug development

    A public docket on challenges in developing botanical drug products. 91 FR 56887; Docket FDA-2026-N-9550. Verified

  4. Aug 11, 2026

    FDA proposes mandatory GRAS notification

    A proposed rule to require GRAS notices for food substances; comments are due December 9, 2026. Self-affirmed GRAS remains lawful until a final rule takes effect. 91 FR 51834. Proposed rule

  5. May 2026

    NCHS reports supplement use among U.S. adults

    60.2% of adults aged 20 and over used a dietary supplement in the past 30 days, August 2021 to August 2023. NCHS Data Brief No. 561. Government data

  6. Nov 28, 2025

    USPTO revises inventorship guidance for AI-assisted inventions

    Relevant to ownership of inventions made with computational tools. 90 FR 54636. Verified

  7. Sep 29, 2025

    FDA letters on NMN and the drug-exclusion sequence

    FDA concluded that NMN is not excluded from the dietary-supplement definition, because marketing as a supplement preceded drug authorization. Reported by Venable LLP; FDA's letters were not reviewed directly. Secondary report

  8. 2025

    U.S. herbal supplement sales estimated at $13.231 billion for 2024

    Up 5.4% from 2023, from Nutrition Business Journal data reported in HerbalGram 144. Retail sales, not ingredient market size. Third-party estimate

  9. May 21, 2024

    ICH M12 on drug interaction studies reaches Step 4

    A harmonized framework for enzyme- and transporter-mediated interaction studies of drugs, useful as a reference for botanical interaction screening. Guideline

  10. Feb 2021

    Bayesian optimization benchmarked against chemists

    In a reaction-optimization benchmark, it outperformed human decision-making in average efficiency and consistency (Shields et al., Nature 2021;590:89–96). Peer-reviewed

  11. 2014 and 2019

    INFOGEST standardizes static in vitro digestion

    An international consensus method (Minekus et al., Food Funct 2014) and a detailed protocol (Brodkorb et al., Nat Protoc 2019) for bioaccessibility screening. Peer-reviewed

Sources: Federal Register 91 FR 66336, 91 FR 56887, 91 FR 51834, 90 FR 54636; FDA event page, "Regulatory Perspectives on Herbal Medicinal/Botanical Drug Product Development – Joint FDA/EMA Workshop"; NCHS Data Brief No. 561 (May 2026); Venable LLP (Oct 2025); Smith, Lang, Craft, HerbalGram 2025;(144):46–69; ICH M12 (Step 4, May 21, 2024); doi:10.1038/s41586-021-03213-y; doi:10.1039/c3fo60702j; doi:10.1038/s41596-018-0119-1. All accessed October 22, 2026.

Interested in collaborating while the company forms?

Scientists, suppliers and potential partners are welcome to start a conversation. Early input shapes what is built first.

Propose a collaborationSupplier inquiry